Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America

Key Points

• Bank of America initiated coverage of Definium Therapeutics with a “buy” rating and a $75 price target, implying 65.71% upside from the prior close.
• Analyst sentiment is broadly positive: MarketBeat reports an average rating of “Buy” and a consensus price target of $63, with two “Strong Buy” and 17 “Buy” ratings versus one “Sell.”
• Shares rose 6.2% to open at $45.26, although the company reported a quarterly loss of $1.44 per share, substantially missing the $0.55 consensus loss estimate. Its lead candidates MM120 and DT402 are advancing in clinical trials for brain-health disorders.

Equities researchers at Bank of America started coverage on shares of Definium Therapeutics (NASDAQ:DFTX - Get Free Report) in a research note issued on Tuesday,Benzinga reports. The firm set a "buy" rating and a $75.00 price target on the stock. Bank of America's price target would indicate a potential upside of 65.71% from the stock's previous close.

Several other analysts also recently commented on the company. Needham & Company LLC raised their price objective on Definium Therapeutics from $50.00 to $66.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Stifel Nicolaus raised their price target on Definium Therapeutics from $30.00 to $60.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Wells Fargo & Company lifted their price objective on Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Maxim Group set a $55.00 target price on Definium Therapeutics and gave the stock a "buy" rating in a research note on Friday. Finally, Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an "outperform" rating in a report on Monday, June 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average price target of $63.00.

Definium Therapeutics Trading Up 6.2%

Shares of NASDAQ DFTX opened at $45.26 on Tuesday. Definium Therapeutics has a fifty-two week low of $8.70 and a fifty-two week high of $49.70. The firm has a market capitalization of $6.08 billion, a P/E ratio of -13.20 and a beta of 2.23. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.95 and a quick ratio of 6.95. The company's 50 day simple moving average is $40.27 and its 200 day simple moving average is $27.09.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). On average, analysts predict that Definium Therapeutics will post -2.81 EPS for the current year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the sale, the chief financial officer owned 209,487 shares of the company's stock, valued at $9,433,199.61. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the business's stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,096 shares of company stock worth $2,165,763 in the last 90 days. Company insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DFTX. Russell Investments Group Ltd. boosted its position in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after acquiring an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock worth $55,000 after purchasing an additional 3,020 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Definium Therapeutics in the third quarter worth $126,000. Mercer Global Advisors Inc. ADV boosted its holdings in Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock worth $259,000 after purchasing an additional 2,079 shares during the last quarter. Finally, Scientech Research LLC acquired a new position in Definium Therapeutics during the third quarter worth $286,000. Institutional investors and hedge funds own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source